z-logo
open-access-imgOpen Access
ODAC Recommends Approval of PathVysion Assay Indicator of Response to Herceptin Therapy for Metastatic Breast Cancer
Author(s) -
Margot J. Fromer
Publication year - 2002
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000315330.48063.0d
Subject(s) - trastuzumab , medicine , metastatic breast cancer , companion diagnostic , breast cancer , oncology , clinical trial , cancer , targeted therapy , gynecology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom